eli lilly and company news

Eli Lilly shares drop

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.

The Wall Street Journal on MSN · 1h

Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Reuters · 3h

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

MarketWatch on MSN · 3h

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

Wall Street Journal · 1h

Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drugs

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.

Eli Lilly acquires cancer program from Scorpion Therapeutics

GlobalData on MSN · 17h

Eli Lilly targets Scorpion Therapeutics to expand reach in oncology

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.

Reuters on MSN · 1d

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire Scorpion's experimental oral therapy,

The Wall Street Journal on MSN · 1d

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

26m

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

1hon MSN

Lilly Shares on Track for Worst Day Since 2021 After Downbeat Zepbound Sales Forecast

The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...

6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Insider Monkey7h

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...

Wall Street Journal44m

Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug

Eli Lilly shares fell after the drugmaker warned that sales of ... of analysts’ projections of $4.4 billion for Mounjaro and $2.1 billion for Zepbound. The company said the U.S. market for these ...

1hon MSN

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

STAT4d

Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund

Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...

Eli Lilly and Company (NYSE:LLY) Shares Acquired by Czech National Bank

Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results